Two additional formulations of ensifentrine are currently in Phase 2 development for the treatment of COPD: dry powder inhaler (“DPI”) and ... outcome; serious adverse, undesirable or unacceptable side effects associated with ...
Source link

Two additional formulations of ensifentrine are currently in Phase 2 development for the treatment of COPD: dry powder inhaler (“DPI”) and ... outcome; serious adverse, undesirable or unacceptable side effects associated with ...
Source link